Immucell stock analysis
Immucell (IUL) Stock Price & Analysis
IUL Stock Chart & Stats
- Day’s Range
- EUR 8.80 - EUR 8.80
- 52-Week Range
- EUR 3.88 - EUR 10.20
- Previous Close
- EUR 9.05
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 79.31M
- Enterprise Value
- EUR 95.94M
- Total Cash (Recent Filing)
- EUR 8.86M
- Total Debt (Recent Filing)
- EUR 12.45M
- Price to Earnings (P/E)
- 120.8
- Beta
- 0.86
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sales Growth And Domestic Traction
Strong sales growth, particularly in the domestic market, indicates expanding commercial adoption and improving channel activity. If sustained, this momentum can increase operating scale, support investment in production, and reinforce the company’s position in cattle health products over the next several quarters.
Conservative Leverage And Cash Generation
The combination of low leverage and positive cash generation gives ImmuCell flexibility to fund operations and strategic investment without relying heavily on external financing. This strengthens resilience during execution challenges and provides capacity to support growth while limiting balance-sheet strain.
Capacity Expansion
The planned capacity investment addresses production scale and processing speed, creating a path to support demand growth while potentially improving unit economics. More than tripling capacity would also reduce operational bottlenecks and give the company a stronger platform for broader product adoption.
Bears Say
Gross Margin Compression
The sharp margin decline shows that recent sales growth is not yet translating consistently into profitable revenue. Lower output, recurring cost reclassification, and scrap have pressured gross profit, and sustained weakness would limit reinvestment capacity and reduce the durability of earnings improvement.
Manufacturing Output Volatility
Volatile production levels create a direct risk to product availability, absorption of fixed manufacturing costs, and gross-margin consistency. Planned pauses and maintenance may support long-term improvements, but near-term execution must stabilize output for the capacity program to deliver its expected benefits.
International Sales Weakness
The international contraction reduces geographic diversification and leaves growth more dependent on the U.S. market. Although part of the decline reflected prior-year backorder clearing, the early-stage international strategy means overseas contribution remains uncertain and may take time to recover.
Immucell News
IUL FAQ
What was Immucell’s price range in the past 12 months?
What is Immucell’s market cap?
When is Immucell’s upcoming earnings report date?
How were Immucell’s earnings last quarter?
Is Immucell overvalued?
Does Immucell pay dividends?
What is Immucell’s EPS estimate?
How many shares outstanding does Immucell have?
What happened to Immucell’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Immucell?
What is the TipRanks Smart Score and how is it calculated?
Immucell Stock Smart Score
Company Description
Immucell
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- F. Olivier Te Boekhorst
- Employees
- 73
- Website
- immucell.com
- Address
- 56 Evergreen Drive, Portland, ME, 04103, US
Immucell (IUL) Earnings & Revenues
IUL Company Deck
IUL Earnings Call
Earnings Call SentimentPositive
The call highlighted meaningful commercial momentum: double-digit product revenue growth (Q2 +11.5%, H1 +20.9%), strong U.S. performance and expanding market share, improved profitability and adjusted EBITDA, and a clearly defined multi‑phase capacity expansion to more than triple production capacity. Offsetting these positives were significant gross margin pressure driven by lower manufacturing output, a recurring cost shift from the discontinued Re-Tain program into COGS, a one-time scrap event (~$150K), and a sharp decline in international sales (–38.9% in Q2). Management presented concrete mitigation steps (yield improvement initiatives, capacity investments, colostrum sourcing programs) and expects to finance most expansion with cash on hand. Overall, the positives (revenue, profitability, working capital strength, and actionable expansion plans) appear to outweigh the operational and margin headwinds, though execution risk remains on manufacturing yields and international ramp.
View all DE:IUL earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 11 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 3 | 0 | 9 |
